Not sure what Jase would say, but I think our partners for the NeoPOLEM study just want to see better treatments for cancer. They are not commercial entities. One is based at the Uni off Southampton (UK) and seems to be UK Govt funded - the other is an Australian not for profit cancer research organisation. The study is "part funded" by them. IMU has not said exactly how much it will cost the company to fund the other part.
The trial partners are described at the end of the official Announcement:
It's a very interesting development. The researchers put have a strong sense that PD1-vaxx will be a highly successful treatment. Recent media releases in the UK certainly sound extremely confident.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)